Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
TRLV vs GLAS: Weighing Scale and Diversification in Cannabis Stocks

TRLV vs GLAS: Weighing Scale and Diversification in Cannabis Stocks

Key Takeaways

  • Tickeron AI Verdict: TRLV stands out as the stronger of the two, backed by greater scale, positive operating cash flow, and operations across multiple states compared with GLAS.
  • TRLV runs about 207 retail dispensaries and posts more than $1 billion in trailing twelve-month revenue, while GLAS remains a smaller California-focused operator with under $200 million in trailing revenue.
  • Both stocks have displayed notable volatility, yet TRLV has held firmer longer-term trend momentum, whereas GLAS has retreated sharply from its 52-week high.
  • TRLV recently completed an uplisting to the New York Stock Exchange, a significant step as one of the first U.S.-based cannabis operators to reach a major U.S. exchange.
  • Additional context is available on each name: GLAS Major News and GLAS Today's Price Move, along with TRLV Major News and TRLV Today's Price Move.
  • To observe how algorithmic strategies are positioned across the market, review Trending AI Robots.

Introduction

Investors following the U.S. cannabis sector often see two distinct operator profiles: large, vertically integrated multi-state companies and smaller, regionally focused cultivators. This comparison looks at GLAS (Glass House Brands Inc.) and TRLV (Trulieve Cannabis Corp.) to show how scale, financial strength, and market reach can differ sharply even inside the same industry. Growth-oriented investors assessing relative performance and risk levels may find the contrast useful, since these two names sit at opposite ends of the sector’s size range. Understanding their business models and recent price behavior helps clarify where each stock fits in the broader cannabis landscape.

GLAS Overview and Recent Performance

GLAS, or Glass House Brands Inc., is a vertically integrated cannabis company centered mainly on the California market. Headquartered in Long Beach, California, and founded in 2015, the company handles greenhouse cultivation, manufacturing, brand development, and retail under names such as Glass House Farms, PLUS Products, Allswell, Forbidden Flowers, and Mama Sue Wellness. It trades on the NYSE and also appears on the OTCQX under the symbol GLASF. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

From a market-positioning standpoint, GLAS is a small-capitalization name, with a market capitalization that has moved in the roughly $120 million to $200 million range in recent weeks. Trailing twelve-month revenue sits near $195 million, while net income stays negative amid ongoing investment and competitive pressure in California’s wholesale cannabis market. In recent trading, the stock has shown considerable volatility and a clear pullback from its 52-week high, highlighting the elevated risk tied to a concentrated, single-state operator.

TRLV Overview and Recent Performance

TRLV, or Trulieve Cannabis Corp., is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. The company cultivates, processes, manufactures, and sells medical and adult-use cannabis, with a strong presence in Florida and additional operations in Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It runs roughly 207 retail dispensaries along with about 3.5 million square feet of cultivation and processing capacity.

With a market capitalization around $1.8 billion and trailing twelve-month revenue of about $1.08 billion, TRLV is considerably larger than many peers and recently became one of the first U.S.-based cannabis companies to uplist to the New York Stock Exchange. The company has produced positive operating profit and levered free cash flow, and it has announced a share repurchase program of up to $50 million. Although the stock has retreated from its 52-week high in recent weeks, its longer-term trend remains positive, with a roughly 80% gain over the trailing 52-week period.

Head-to-Head Comparison

The clearest difference between these two cannabis operators lies in scale and diversification. TRLV operates across multiple states with a leading position in Florida, giving it a wider revenue base and greater geographic resilience than GLAS, whose results are closely tied to California’s wholesale and retail cannabis conditions. On financial fundamentals, TRLV generates positive operating profit and free cash flow, while GLAS continues to report negative net income.

Risk profiles also differ in meaningful ways. TRLV carries a higher beta, reflecting greater sensitivity to broader market moves, yet its fundamentals provide more stability. GLAS, as a small-cap single-state operator, faces concentrated regulatory and pricing risk. In recent momentum, both names have declined from higher levels, but TRLV keeps a stronger trailing 52-week trend, while GLAS has seen a steeper drawdown.

Tickeron AI Verdict

Based on observable factors such as scale, cash-flow generation, geographic diversification, and trend consistency, Tickeron’s AI currently favors TRLV over GLAS. The multi-state operator’s positive operating cash flow, larger revenue base, and recent exchange uplisting represent comparatively stronger catalysts and stability signals. GLAS’s concentrated California exposure and negative earnings introduce greater uncertainty into its outlook. These observations reflect probabilistic positioning rather than a definitive prediction, and conditions can shift as new data emerges.

AI Tools in My Research

I’ve found Tickeron’s Trending AI Robots page helpful when reviewing how automated strategies are currently positioned across sectors like cannabis. It offers a focused view of bots that adapt to shifting conditions, letting me compare different approaches without relying on any single method.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TRLV, GLAS

Momentum Indicator for TRLV turns negative, indicating new downward trend

TRLV saw its Momentum Indicator move below the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 78 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TRLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 30 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

TRLV moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for TRLV's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 186 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

TRLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 135 of 157 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.901) is normal, around the industry mean (6.379). P/E Ratio (-4.680) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 8 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
3494 Martin Hurst Road
Phone
+1 850 298-8866
Employees
5000
Web
https://www.trulieve.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.